|
 The round of funding, led by the KCK Group and OrbiMed Advisors, is
likely to be the Mountain View-based company's last as it plans to
go public.
"Our strategy is to take the company public," Chief Executive Frank
Fischer told Reuters, hinting at a possible IPO by the second half
of 2019.
Once implanted in the skull, NeuroPace's RNS System constantly
monitors brain waves, identifying and disrupting unusual activity
that may trigger seizures.
At least 3.4 million people in the United States suffer from
epilepsy, according to the Centers for Disease Control and
Prevention.
The company's RNS System was approved in 2013 by the U.S. Food and
Drug Administration.
NeuroPace, which estimates about 450 patients will be implanted with
the device this year, hopes to double that number in 2018.
[to top of second column] |
Patients can also download data gathered by the RNS System, which
can be studied by physicians to aid treatment by, for example,
identifying the time of day a patient might be most susceptible to a
seizure.
This feature could offer the medical community greater understanding
of a little-understood disease whose past treatments included animal
sacrifice and exorcism.
(Reporting by Tamara Mathias in Bengaluru; Editing by Shounak
Dasgupta)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
